Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats

Journal of Orthopaedic Surgery and Research

Volumn 6, Issue 1, 2011, Pages

  Wang, Yan ^a   Huang, Peng ^a   Tang, Pei Fu ^a   Chan, Kai Ming ^b   Li, Gang ^b,c  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Alendronate; Osteoporosis; Osteoprotegerin; Ovariectomy; RANKL

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE; BONE DENSITY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; METABOLISM; OSTEOLYSIS; OVARIECTOMY; RAT; SPRAGUE DAWLEY RAT;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; DRUG THERAPY, COMBINATION; FEMALE; MODELS, ANIMAL; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79960129388     PISSN: None     EISSN: 1749799X     Source Type: Journal    
DOI: 10.1186/1749-799X-6-34     Document Type: Article

References (25)

1. Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ. Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone 2000, 26:443-449. 10.1016/S8756-3282(00)00256-8, 10773583.
2. Nishida S, Tsubaki M, Hoshino M. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 2005, 328:91-97. 10.1016/j.bbrc.2004.12.145, 15670755.
3. Huang P, Wang Y, Chi Z, Yang Z, Ni J, Yang W, Wang R. In vitro study of combination rhOPG-FC and Alendronate on inhibiting osteoclastogenesis. Chin J Surg 2005, 43:812-816.
4. Miyazaki S, Igarashi M, Nagata A, Tominaga Y, Onodera K, Komoda T. Development of immunoassays for type-5 tartrate-resistant acid phosphatase in human serum. Clin Chim Acta 2003, 329:109-115. 10.1016/S0009-8981(02)00431-X, 12589973.
5. Nosjean O, Koyama I, Goseki M, Roux B, Komoda T. Human tissue non-specific alkaline phosphatases: Sugarmoiety-induced enzymic and antigenic modulations and genetic aspects. Biochem J 1997, 21:7-303.
6. Turner CH, Burr DB. Basic biomechanical measurements of bone: A tutorial. Bone 1993, 14:595-690. 10.1016/8756-3282(93)90081-K, 8274302.
7. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 1987, 2:595-610.
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction ofstromal cells with osteoclast. Biochem Biophys Res Commun 1998, 250:229-234. 10.1006/bbrc.1998.9294, 9753612.
9. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234:137-142. 10.1006/bbrc.1997.6603, 9168977.
10. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998, 250:229-234. 10.1006/bbrc.1998.9294, 9753612.
11. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino ACW, Hay S, Findlay DM. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 2001, 28:370-377. 10.1016/S8756-3282(01)00404-5, 11336917.
12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Hsu H, Sullivan J, Hakins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senalddi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X, 9568710.
13. Tsukii K, Shima N, Mochizuki N, Yamaguchi K, Kionosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998, 246:337-341. 10.1006/bbrc.1998.8610, 9610359.
14. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000, 141:3478-3484. 10.1210/en.141.9.3478, 10965921.
15. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, ashida N, Tsuda E, Morinaga T, Higashio K, Ozawa H. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615. 10.1006/bbrc.1998.8697, 9647741.
16. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y. Immunological characterization of circulating osteoprotegerin osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999, 14:518-527. 10.1359/jbmr.1999.14.4.518, 10234572.
17. Van Beek E, Lowik C, Van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999, 14:722-729. 10.1359/jbmr.1999.14.5.722, 10320520.
18. Bone HG, Hosking D, Devogelaer JP, Tucci JR. Ten years' experience with Alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-99. 10.1056/NEJMoa030897, 15028823.
19. Mosekilde L, Danielsen CC, Knudsen UB. The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 1993, 14:1-6.
20. Fuchs RK, Shea M, Durski SL, Winters-Stone KM, Widrick J, Snow CM. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 2007, 41:290-296. 10.1016/j.bone.2007.04.179, 17544352.
21. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003, 18:852-858. 10.1359/jbmr.2003.18.5.852, 12733724.
22. Bergstrom JD, Bostedor RG, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231-241. 10.1006/abbi.1999.1502, 10620343.
23. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269. 10.1146/annurev.bi.65.070196.001325, 8811180.
24. Zhang D, Udagawa N, Nakamura I. The small GPT-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995, 108:2285-2292.
25. Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science 1993, 259:1865-1866. 10.1126/science.8456312, 8456312.